Navigation Links
Alzheimer's Drug Discovery Foundation Supports Axxam To Develop Novel Therapeutics for Alzheimer's Disease
Date:6/22/2011

NEW YORK, June 22, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant to Axxam SpA to develop small molecules to treat Alzheimer's disease by targeting inflammation.

(Logo: http://photos.prnewswire.com/prnh/20090805/DC57332LOGO)

The award will fund a drug discovery project to identify compounds that block the puringeric receptor, P2X7, which is involved in inflammation in the brain.  One of the characteristic features of Alzheimer's disease is a robust inflammatory response involving over-activation of specialized brain cells called microglia and the release of pro-inflammatory signals associated with the deposition of Alzheimer's disease plaques in the brain.  These pro-inflammatory signals are closely associated with the P2X7 receptor, putting this novel target at the heart of brain inflammation.

"Compounds that block P2X7 may treat brain inflammation and can potentially be useful in the treatment of Alzheimer's disease and other neurodegenerative diseases," said Howard Fillit, MD, Executive Director, ADDF.  "P2X7 is a novel target and we are excited to fund the program and investigate its therapeutic potential."

"We are pleased to be selected by the ADDF for this peer-reviewed grant, which recognizes the quality of our research capabilities in the challenging field of neuroinflammation." Said Stefan Lohmer, co-founder and CEO of Axxam.  "We are looking forward to working with the ADDF team and moving our Alzheimer's disease program forward."

For more information about the ADDF or to speak with Dr. Fillit, please contact Filomena Machleder at 212-901-8004 or fmachleder@alzdiscovery.org.  For more information about Axxam, please contact Stefan Lohmer, PhD, CEO, Axxam at +39 02 2105622 or stefan.lohmer.sl@axxam.com.

About the Alzheimer's Drug Discovery Foundation (www.AlzDiscovery.org)
The Alzheimer's Drug Discovery Foundation (ADDF) is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $50 million to fund over 325 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 19 countries. 

About Axxam SpA (www.axxam.com)
Axxam is a privately owned contract research and discovery company located at the San Raffaele Biomedical Science Park in Milan, Italy.  The company has developed a proven track record as a third party research and discovery services provider for the life science industry.  In addition, Axxam conducts several discovery programs for selected targets which are carried out in partnership with other companies or non-profit organizations.

CONTACT: Filomena Machleder, +1-212-901-8004, fmachleder@alzdiscovery.org; Stefan Lohmer, PhD, CEO, Axxam, +39-02-2105622, stefan.lohmer.sl@axxam.com


'/>"/>
SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Yuma Therapeutics Awarded a Research Grant by the Alzheimers Drug Discovery Foundation to Develop Novel Therapeutics for Alzheimers Disease
2. Alzheimers Drug Discovery Foundation Supports ADispell Technology with a Grant to Advance Novel Drug Candidates for Alzheimers Disease
3. GE Discovery ST Installed at Imaging Healthcare Specialists
4. Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government
5. Dave Anderson and William Thomsen Join SRI Internationals Center for Advanced Drug Research to Lead Programs in Proteomics and Metabolic Disease Drug Discovery
6. Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
7. Caliper Life Sciences IVIS® Optical Imaging System Adoption Surpasses 1000 Units: Validated Drug Research, Discovery and Development Tool Enables Advances in Personalized Medicine
8. BioSurplus Selected to Liquidate Discovery Laboratory Equipment
9. PTC Therapeutics and Parent Project Muscular Dystrophy Advance Drug Discovery Program to Improve Heart Function in Duchenne/Becker Muscular Dystrophy Patients
10. Reportlinker Adds The Drug Discovery Outsourcing Market
11. Collaborative Drug Discovery Receives New Funding to Support Tuberculosis Drug Discovery Screening Efforts and Industrial-Academic Collaborations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
Breaking Medicine News(10 mins):